Financial Ratios

COLINZ LABORATORIES LTD.

NSE : NABSE : 531210ISIN CODE : INE923C01011Industry : Pharmaceuticals & DrugsHouse : Private
BSE39.75-0.26 (-0.65 %)
PREV CLOSE ( ) 40.01
OPEN PRICE ( ) 39.01
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 613
TODAY'S LOW / HIGH ( )39.01 40.00
52 WK LOW / HIGH ( ) 33.3546.9
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)1.820.960.590.370.34
   CEPS(Rs)2.331.521.130.920.95
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)32.3121.6920.5719.2919.31
   Tax Rate(%)23.7429.3615.3325.9121.84
Margin Ratios
   Core EBITDA Margin(%)8.518.405.393.984.57
   EBIT Margin(%)9.117.975.393.193.30
   Pre Tax Margin(%)8.386.893.982.322.03
   PAT Margin (%)6.394.873.371.721.59
   Cash Profit Margin (%)8.197.756.484.284.40
Performance Ratios
   ROA(%)4.543.392.201.451.30
   ROE(%)5.784.532.941.911.79
   ROCE(%)7.866.764.283.303.45
   Asset Turnover(x)0.710.700.650.850.82
   Sales/Fixed Asset(x)1.091.010.911.141.15
   Working Capital/Sales(x)1.201.291.311.801.99
Efficiency Ratios
   Fixed Capital/Sales(x)0.910.991.100.880.87
   Receivable days59.6965.5182.6476.0679.98
   Inventory Days47.5556.8387.0586.1692.02
   Payable days89.8980.9276.3447.3766.26
Valuation Parameters
   PER(x)19.2824.6012.9824.2618.95
   PCE(x)15.0415.456.759.736.83
   Price/Book(x)1.081.090.370.460.34
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)0.470.52-0.160.130.13
   EV/Core EBITDA(x)4.304.79-1.902.172.11
   EV/EBIT(x)5.156.53-3.003.903.91
   EV/CE(x)0.330.37-0.100.110.11
   M Cap / Sales1.241.200.440.420.30
Growth Ratio
   Net Sales Growth(%)2.7513.61-18.88-0.62-4.04
   Core EBITDA Growth(%)3.1844.7219.51-6.692.80
   EBIT Growth(%)17.3367.5636.59-4.077.66
   PAT Growth(%)34.8163.4459.147.15-47.22
   EPS Growth(%)89.7063.4459.097.16-47.22
Financial Stability Ratios
   Total Debt/Equity(x)0.030.060.140.060.10
   Current Ratio(x)4.153.722.813.633.16
   Quick Ratio(x)3.663.262.332.582.09
   Interest Cover(x)12.477.363.833.642.60
   Total Debt/Mcap(x)0.030.050.290.090.23

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.